Contemporary lipid guidelines are often portrayed as divergent, creating uncertainty about optimal lipid-lowering strategies in clinical practice. However, major contemporary recommendations—including the 2025 European guidelines, the 2026 American guidelines, the Lipid Association of India (LAI) consensus, and the International Lipid Expert Panel (ILEP) statements—demonstrate substantial conceptual convergence. All endorse earlier identification of high- and extreme-risk phenotypes, intensive lowering of low-density lipoprotein cholesterol (LDL-C) and apolipoprotein B, and prompt use of combination lipid-lowering therapy when monotherapy is unlikely to achieve therapeutic goals. Although differences persist in risk assessment tools, imaging utilization, and implementation frameworks, these largely reflect regional epidemiology, healthcare systems, and affordability rather than fundamental scientific disagreement. Across primary and secondary prevention settings, the unifying paradigm is increasingly “earlier, lower, longer,” emphasizing cumulative lifetime exposure to atherogenic lipoproteins as the principal determinant of atherosclerotic cardiovascular disease risk. The major challenge is therefore no longer guideline discordance, but translating convergent evidence into systematic, timely, and sustained implementation in routine care.
Sethi et al. (Thu,) studied this question.